Table 1.
List of FLT3 associated genetic alterations identified in 1540 acute myeloid leukemia (AML) patients, as reported by Papaemmanuil et al. [9].
| Frequency of FLT3 Co-Occurrent Mutated Genes (N = 512) | Frequency of FLT3 Co-Occurrent Mutated Pairs (N = 512) | ||
|---|---|---|---|
| Gene | n of Patients (%) | Gene | n of Patients (%) |
| NPM1 | 242 (47.3) | NPM1:DNMT3A | 130 (25.4) |
| DNMT3A | 168 (32.8) | TET2:NPM1 | 35 (6.8) |
| TET2 | 59 (11.5) | NPM1:IDH1 | 24 (4.7) |
| NRAS | 51 (9,9) | NPM1:IDH2 | 24(4.7) |
| RUNX1 | 40 (7.8) | NRAS:NPM1 | 21 (4.1) |
| WT1 | 37 (7.2) | PTPN11:NPM1 | 21 (4.1) |
| CEBPA | 36 (7.0) | RAD21:NPM1 | 20 (3.9) |
| MLL | 35 (6.8) | TET2:DNMT3A | 19 (3.7) |
| IDH1 | 34 (6.6) | IDH1:DNMT3A | 16 (3.1) |
| IDH2 | 33 (6.4) | IDH2:DNMT3A | 16 (3.1) |
| PTPN11 | 29 (5.7) | MLL:DNMT3A | 15 (2.9) |
| RAD21 | 29 (5.7) | NRAS:DNMT3A | 15 (2.9) |
| SFRS2 | 15 (2.9) | RUNX1:DNMT3A | 13 (2.5) |
| MYC | 14 (2.7) | WT1:NPM1 | 13 (2.5) |
| ASXL1 | 12 (2.3) | DNMT3A:CEBPA | 11 (2.1) |
| CBL | 12 (2.3) | RUNX1:MLL | 11(2.1) |
| EZH2 | 12 (2.3) | NPM1:MYC | 8 (1.6) |
| KRAS | 12 (2.3) | SFRS2:RUNX1 | 8 (1.6) |
| PHF6 | 11 (2.1) | STAG2:NPM1 | 8 (1.6) |
| KIT | 10 (1.9) | NPM1:KRAS | 7 (1.4) |
| GATA2 | 9 (1.7) | RAD21: DNMT3A | 7 (1.4) |
| SF3B1 | 8 (1.6) | TET2:RUNX1 | 7 (1.4) |
| MLL2 | 7 (1.4) | KRAS:DNMT3A | 6 (1.2) |
| TP53 | 7 (1.4) | PHF6:NPM1 | 6 (1.2) |
| U2AF1 | 7 (1.4) | RUNX1:NRAS | 6 (1.2) |
| NF1 | 6 (1.2) | TET2:MLL | 6 (1.2) |
| ZRSR2 | 5 (1) | TET2:PTPN11 | 6 (1.2) |
| NPM1:NF1 | 5 (0.9) | ||
| NRAS:KRAS | 5 (0.9) | ||
| RUNX1:EZH2 | 5 (0.9) | ||
| STAG2:MLL | 5 (0.9) | ||
| TET2:RAD21 | 5 (0.9) | ||
| TET2:STAG2 | 5 (0.9) | ||